DATA Globaldata Plc

RNS Number:9504F
Provalis PLC
09 January 2003


For Immediate Release                                             9 January 2002





             Provalis plc - Half Year Trading Update - Sales up 92%





Provalis plc (LSE: PRO; NASDAQ:PVLS), the Medical Diagnostics and
Pharmaceuticals group, is pleased to announce that unaudited sales for the half
year to 31st December 2002 were up 92% at approximately #7.1 million - compared
to the same period in the previous year (#3.7 million).



Significant progress has been made by both operating divisions of the Company:-



In Medical Diagnostics, Glycosal has been very successful, with a major growth
in sales, particularly in the USA, following the appointment of a strong
distributor for the product.  Sales for the division in this six month period
were #1.6 million, compared with sales of #0.9 million for the whole of the last
financial year.



Healthcare sales were #5.5 million, 77% up on the same period last year and 8%
up compared with the second half of the last financial year. This reflects the
continuing strong performance of Diclomax, which was acquired in December 2001.



Cash-burn related to vaccines will reduce significantly in 2003. The proposed
disposal of our  vaccines programmes has progressed slowly, with the valuations
placed on them by third parties being insufficient to justify their disposal in
a single transaction.  Accordingly, Provalis has stopped all major spend within
the Vaccines R & D division, other than direct patent support.  Provalis has
retained its interest in those programmes already licensed to, and funded by,
third parties, and will continue to seek the divestment of other programmes.



Phil Gould, CEO of Provalis, commented: "The first half of the current financial
year has seen strong growth in sales, particularly in the Medical Diagnostics
division. The take-up of Glycosal instruments should lead to significant
follow-on orders for Glycosal test cartridges in the months and years ahead.
Meanwhile, the savings from the rationalisation of the Vaccine division will
assist Provalis' progress towards financial self sufficiency. By retaining our
interest in the programmes funded and run by third parties, we can still benefit
from any future commercial upside."



The Company's interim figures and an overview of trading expectations for the
full year will be presented in March 2003.



                                      END



Provalis' Internet Website; http://www.provalis.com



"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of
1995: Statements in this announcement that relate to future plans, expectations,
events, performances and the like are forward-looking statements as defined in
the US Private Securities Litigation Reform Act of 1995. Actual results of
events could differ materially from those described in the forward-looking
statements due to a variety of factors.  Such factors include, among others: the
success of the Group's research and development strategy; uncertainties related
to future trial results and the regulatory process; the execution and success of
collaborative agreements with third parties; the impact of future laws,
regulations and policies; the Group's intellectual property position and the
success of patent applications for its products and technologies; stock market
trends in the Group's sector; the Group's dependence on key personnel; general
business and economic conditions; and other factors beyond the Group's control
that may cause the Group's available capital resources to be used more quickly
than expected.  These and other factors that could affect the Company's future
results are more fully described in its filings with the US Securities and
Exchange Commission, in particular the latest 20-F filing, copies of which are
available from the Company Secretary at the Company's registered address.



For further information:-



Dr Phil Gould, Provalis plc,  Tel:  01244 833 463

Mr Neil Kirkby, Provalis plc,  Tel: 01244 833 552

Mr Lee Greenbury, Provalis plc,  Tel:  01244 833 402

Lisa Baderoon, Buchanan Communications,  Tel:  020 7466 5000



Notes to Editors



Provalis plc (LSE:PRO and NASDAQ:PVLS) is a pharmaceutical company with two
operating divisions:-



Medical Diagnostics - develops and sells to world markets medical diagnostic
products for chronic disease management.  The division's principle products are
Glycosal and Osteosal in the areas of diabetes and osteoporosis respectively.



Healthcare - sells and markets its own, and third party, branded, prescription
medicines in the UK to GPs and hospitals through its own regionally managed
sales force.  The division's principle product is Diclomax, a medicine for use
in the treatment of musculo-skeletal disorders, and it also sells products in
the areas of gastroenterology, osteoporosis, migraine and dermatology.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

TSTEAXFPEDSDEFE

Globaldata (LSE:DATA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024

Globaldata (LSE:DATA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024